Severity
Critical
FDA Drug recall · Reported October 20, 2021
SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration.
Eli Lilly & Company recalled Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluen… - a critical-severity action.
Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluen… was recalled by Eli Lilly & Company in October 20, 2021. Reason: SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also …. Check the official notice for the remedy. Verify recall #D-0009-2022 with the FDA Drug before acting.
The recall
Eli Lilly & Company issued this critical-severity FDA Drug recall-SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also ….
Sourced from official FDA Drug enforcement records. Verify recall #D-0009-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0009-2022) was formally reported on October 20, 2021, with the manufacturer initiating the action on September 24, 2021. It is classified under Critical severity (Class I), with a current status of Terminated. Eli Lilly & Company is listed as the recalling firm, operating out of Indianapolis, IN. Federal records list the affected scope as 19,174 syringes.
The documented reason for this recall is: SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration. Distribution data in the federal record shows the product reached: Nationwide with the USA and Puerto Rico; Canada, Argentina, Costa Rica, Mexico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
19,174 syringes
Related Recalls
6
5 from same agency
Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe. Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285; Glucagon, NDC: 0002-8031-01
SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-0009-2022 |
| Date reported | October 20, 2021 |
| Date initiated | September 24, 2021 |
| Recalling firm | Eli Lilly & Company |
| Firm location | Indianapolis, IN |
| Affected scope | 19,174 syringes |
| Distribution | Nationwide with the USA and Puerto Rico; Canada, Argentina, Costa Rica, Mexico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported October 20, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.